{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 37,
  "pageCount": 366,
  "prevPage": 36,
  "nextPage": 38,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a narrative structure to link a specific company's strategy to a broader pattern of behavior.",
  "elementsJson": [
    "paragraph",
    "headline_text",
    "footnote"
  ],
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/37",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-37",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Aronin’s company Castle Creek follows his usual playbook, similar to the one for Harmony: licensing an old, toxic foreign drug and trying to win FDA approval for a rare drug indication in order to spike the price.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9ccb-3687fb48e8bb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "Aronin’s company Castle Creek follows his usual playbook, similar to the one for Harmony: licensing an old, toxic foreign drug and trying to win FDA approval for a rare drug indication in order to spike the price.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e32eb3b-c75b-4df9-83e7-566182989430",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.86,
        "x": 0.07,
        "y": 0.84
      },
      "kind": "paragraph",
      "text": "Committee cites concerns over gastro-intestinal side effects and liver toxicity",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "379754fc-d70c-49b1-acee-174b9c1dd57e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.51
      },
      "kind": "paragraph",
      "text": "In Castle Creek’s case, they took an old drug that is marketed in a variety of countries around the world for osteoarthritis — 50 mg diacerein — and reformulated the IL-1 beta anti-inflammatory drug into a topical treatment for an ultra-rare fragile skin disease called epidermolysis bullosa.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a3b38bd-5bc8-4211-a8b5-11072723caa6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.07,
        "y": 0.41
      },
      "kind": "paragraph",
      "text": "Fresh from a $72M raise, Jeff Aronin's new lead rare disease drug is flagged as a failure",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c955d78e-2a88-480b-9c15-b95adad35150",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "PRAC recommends suspension of diacerein-containing medicines — Committee cites concerns over gastro-intestinal side effects and liver toxicity",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9ccb-3a5828f4378b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.86,
        "x": 0.07,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Source: https://endpts.com/fresh-from-a-72m-raise-jeff-aronins-new-lead-rare-disease-drug-is-flagged-as-a-failure/; https://www.aifa.gov.it/sites/default/files/Diacerein%20Summary%20of%20PRAC%20recommendation.pdf",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3e8e6ec-0cbb-48f8-9d7b-b170e27873ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.86,
        "x": 0.07,
        "y": 0.78
      },
      "kind": "title",
      "text": "PRAC recommends suspension of diacerein-containing medicines",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "548b558a-1bbf-49b5-a2b5-b5a4796717b9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "2db66767-ab6d-4e9c-98e9-7c7817a40d0f",
      "evidence": "The slide explicitly frames the company's actions as a 'playbook' for 'price gouging' using 'toxic' drugs.",
      "confidence": 0.85
    }
  ],
  "arcBeats": [
    {
      "to": 50,
      "from": 31,
      "beatId": "2b789ae4-940c-4d3a-9f03-7f2e7e4f46fd",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Struggle",
      "beatSlug": null,
      "evidence": "The document presents the struggle of the company's critics and short-sellers to expose the truth",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}